MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

Hand writing the text: Top 100

For companies leading the global medical technology industry, the latest MTI 100 sales rankings are strikingly similar to last year's list, with a handful of major exceptions.

Among the top-10 revenue-earners, Abbott Laboratories Inc. made the biggest jump in position, from spot number 10 to five, based on the fruits of its vigorous M&A activity. All of the top 10 revenue-earners recorded sales of over $10bn, with the acquisitive Boston Scientific Corp. (electrophysiology company Apama Medical Inc

The MTI 100 is Medtech Insight's annual revenue ranking of the top 100 device and diagnostics companies, by revenue, and the top 10 players in the cardiology, IVD, orthopedic and imaging sectors. The full tables are below and also on the MTI 100 home page

More from Business

More from Medtech Insight

Beyond The Bladder: Incontinence Impacts Mental Health

 

In recognition of Mental Health Awareness month, Sarah Jenkins, executive director at the National Association for Continence, discussed the mental health issues that often come with incontinence.

AI Rollout Aims To Accelerate FDA’s Product Review Process

 
• By 

The FDA plans to implement artificial intelligence in its scientific review process by 30 June, following a successful pilot. The agency hopes the tool will reduce nonproductive tasks for reviewers amid recent staff cuts. A Chief AI Officer will oversee the rollout and integration.

Access To Library Tools Being Restored At US FDA

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.